Published Online
on August 4, 2003

A more recent version of this article appeared on August 12, 2003

This Article Full Text (PDF) All Versions of this Article: 108/6/664    most recent 01.CIR.0000086978.95976.41v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cook, S. A. Articles by Rosenzweig, A. Search for Related Content PubMed PubMed Citation Articles by Cook, S. A. Articles by Rosenzweig, A. Related Collections Cell signalling/signal transduction Hypertrophy Gene therapy Related Article

Submitted on May 2, 2003
Revised on June 18, 2003
Accepted on June 19, 2003

A20 Is Dynamically Regulated in the Heart and Inhibits the Hypertrophic Response

Stuart A. Cook MRCP, PhD, Mikhail S. Novikov MD, Youngkeun Ahn MD, PhD, Takashi Matsui MD, PhD, and Anthony Rosenzweig MD^*

From the Program in Cardiovascular Gene Therapy, Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

^* To whom correspondence should be addressed. E-mail: arosenzweig{at}partners.org.

Background--Nuclear factor (NF)-B signaling has been implicated in cardiomyocyte hypertrophy. Here, we determine the cardiac regulation and biological activity of A20, an inhibitor of NF-B signaling.

Methods and Results--Mice were subjected to aortic banding, and A20 expression was examined. A20 mRNA upregulation (4.3±1.5-fold; P<0.05) was detected 3 hours after banding, coinciding with peak NF-B activation. A20 was also upregulated in cultured neonatal cardiomyocytes stimulated with phenylephrine or endothelin-1 (2.8±0.6- and 4±1.1-fold, respectively; P<0.05), again paralleling NF-B activation. Infection of cardiomyocytes with an adenoviral vector (Ad) encoding A20 inhibited tumor necrosis factor--stimulated NF-B signaling with an efficacy comparable to dominant negative IKK (dnIKK). Ad.dnIKK-infected cardiomyocytes exhibited increased apoptosis when they were serum starved or subjected to hypoxia-reoxygenation, whereas Ad.A20-infected cardiomyocytes did not. Expression of Ad.A20 inhibited the hypertrophic response in cardiomyocytes stimulated with phenylephrine or endothelin-1.

Conclusions--A20 is dynamically regulated during acute biomechanical stress in the heart and functions to attenuate cardiac hypertrophy through the inhibition of NF-B signaling without sensitizing cardiomyocytes to apoptotic cell death.

Key words: hypertrophy • apoptosis • inflammation

Related Article:

Is Nuclear Factor B an Attractive Therapeutic Target for Treating Cardiac Hypertrophy?

Nicole H. Purcell and Jeffery D. Molkentin
Circulation 2003 108: 638-640. [Extract] [Full Text]

This article has been cited by other articles:

				S. Wu, R. Yin, R. Ernest, Y. Li, O. Zhelyabovska, J. Luo, Y. Yang, and Q. Yang Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-{kappa}B signalling Cardiovasc Res, October 1, 2009; 84(1): 119 - 126. [Abstract] [Full Text] [PDF]

				J. Shaw, I. A. Eydelnant, and L. A. Kirshenbaum Transgenic Expression of A20 Prevents Cardiac Cell Death and Myocardial Dysfunction After Myocardial Infarction Circulation, April 10, 2007; 115(14): 1827 - 1829. [Full Text] [PDF]

				H.-L. Li, M.-L. Zhuo, D. Wang, A.-B. Wang, H. Cai, L.-H. Sun, Q. Yang, Y. Huang, Y.-S. Wei, P. P. Liu, et al. Targeted Cardiac Overexpression of A20 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction Circulation, April 10, 2007; 115(14): 1885 - 1894. [Abstract] [Full Text] [PDF]

				T. Ha, F. Hua, Y. Li, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. W. Browder, et al. Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H985 - H994. [Abstract] [Full Text] [PDF]

				J. Backs and E. N. Olson Control of Cardiac Growth by Histone Acetylation/Deacetylation Circ. Res., January 6, 2006; 98(1): 15 - 24. [Abstract] [Full Text] [PDF]

				T. Ha, Y. Li, F. Hua, J. Ma, X. Gao, J. Kelley, A. Zhao, G. E. Haddad, D. L. Williams, I. William Browder, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload Cardiovasc Res, November 1, 2005; 68(2): 224 - 234. [Abstract] [Full Text] [PDF]

				W. Chao, Y. Shen, L. Li, H. Zhao, S. E. Meiler, S. A. Cook, and A. Rosenzweig Fas-associated death-domain protein inhibits TNF-{alpha} mediated NF-{kappa}B activation in cardiomyocytes Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2073 - H2080. [Abstract] [Full Text] [PDF]

				S. Gupta, D. Young, and S. Sen Inhibition of NF-{kappa}B induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H20 - H29. [Abstract] [Full Text] [PDF]

				T. Kiji, Y. Dohi, S. Takasawa, H. Okamoto, A. Nonomura, and S. Taniguchi Activation of regenerating gene Reg in rat and human hearts in response to acute stress Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H277 - H284. [Abstract] [Full Text] [PDF]

				T. Aoyama, T. Matsui, M. Novikov, J. Park, B. Hemmings, and A. Rosenzweig Serum and Glucocorticoid-Responsive Kinase-1 Regulates Cardiomyocyte Survival and Hypertrophic Response Circulation, April 5, 2005; 111(13): 1652 - 1659. [Abstract] [Full Text] [PDF]

				B. Chandrasekar, S. Mummidi, W. C. Claycomb, R. Mestril, and M. Nemer Interleukin-18 Is a Pro-hypertrophic Cytokine That Acts through a Phosphatidylinositol 3-Kinase-Phosphoinositide-dependent Kinase-1-Akt-GATA4 Signaling Pathway in Cardiomyocytes J. Biol. Chem., February 11, 2005; 280(6): 4553 - 4567. [Abstract] [Full Text] [PDF]

				K. M. Regula, D. Baetz, and L. A. Kirshenbaum Nuclear Factor-{kappa}B Represses Hypoxia-Induced Mitochondrial Defects and Cell Death of Ventricular Myocytes Circulation, December 21, 2004; 110(25): 3795 - 3802. [Abstract] [Full Text] [PDF]

				B. C. Harrison, C. R. Roberts, D. B. Hood, M. Sweeney, J. M. Gould, E. W. Bush, and T. A. McKinsey The CRM1 Nuclear Export Receptor Controls Pathological Cardiac Gene Expression Mol. Cell. Biol., December 15, 2004; 24(24): 10636 - 10649. [Abstract] [Full Text] [PDF]

				Y. Li, T. Ha, X. Gao, J. Kelley, D. L. Williams, I. W. Browder, R. L. Kao, and C. Li NF-{kappa}B activation is required for the development of cardiac hypertrophy in vivo Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1712 - H1720. [Abstract] [Full Text] [PDF]

				S. E Hardt and J. Sadoshima Negative regulators of cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 500 - 509. [Abstract] [Full Text] [PDF]

				N. H. Purcell and J. D. Molkentin Is Nuclear Factor {kappa}B an Attractive Therapeutic Target for Treating Cardiac Hypertrophy? Circulation, August 12, 2003; 108(6): 638 - 640. [Full Text] [PDF]